Date: 8-9 March 2016
Venue: IET London, Savoy Place, London, WC2R 0BL, UK
Twitter: #lsemedtech
The second LSE Summit will explore the challenges and opportunities around the regulation and value assessment of medical technologies.
Incomplete evidence on the added therapeutic benefit of new medical technologies often limits the ability of regulators and decision-makers to make optimal resource allocation decisions. The need for a more flexible and dynamic approach to evidence-based decision-making is increasingly recognised and reflected in current international and national initiatives.
These include, first, the need for a more flexible approach towards marketing authorisation and greater alignment with health technology assessment to create synergies and avoid duplications (adaptive pathways and early policy dialogues); second, initiatives to improve methodological approaches to assess value along the drug development continuum; third, an increasing use of managed entry/risk-sharing agreements to manage the introduction of new medicines; fourth, the need to work more closely with the innovators to incentivise optimal R&D decisions for society in areas of high unmet need (eg antibiotics and rare diseases); and, finally, initiatives concerning reward based on value such as value-based assessment and pricing, which could also influence the coverage and reimbursement of products with multiple indications.
This summit brings all these trends together and provides a dynamic forum for interaction and debate by the broader stakeholder community. Speakers from national competent authorities on pricing, reimbursement and HTA, pharmaceutical manufacturers, international organisations, patient representative organisations and academia will provide their views on these latest developments, future perspectives and policy options during this two-day summit in London. Most importantly, the summit will allow plenty of time for plenary discussions with the participants and networking.
